Middle East & Africa Blood Plasma Derivatives Market

The Middle East & Africa blood plasma derivatives market was valued at US$ 1,402.51 million in 2022 and is projected to reach US$ 2,223.69 million by 2028; it is expected to grow at a CAGR of 8.0% from 2022 to 2028.

Increasing Usage of Immunoglobulin G in Multiple Treatments is Driving the Middle East & Africa Blood Plasma Derivatives Market

Immunoglobulin G (IgG) therapies are highly used to treat primary immune deficiency cause by the genetics. The demand for IgG has been increasing steadily for the last few years due to the increasing awareness of IgG therapy. The growth is also accounted for its new therapy for its newly identified indication. Based on controlled trials done by Network Meta Analysis (NMA), IgG therapy has been approved for the treatment of Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and dermatomyositis. The Immunoglobulin G (IgG) therapies is also effective for the treatment of myasthenia gravis exacerbations and stiff-person syndrome. In addition, it provides convincing efficacy in autoimmune disorders like epilepsy, neuromyelitis, and autoimmune encephalitis.

A large proportion of IgG is used in specialties outside of immunology, such as oncology, neurology, hematology, and rheumatology. Compared to all, neurology is the fastest-growing specialty in the global market. The growth of the Immunoglobulin G market is attributed due to its approved for on-label use for chronic inflammatory demyelinating polyneuropathy (CIDP) followed by its off-label use in secondary immune deficiencies caused by lymphoma, myeloma, and leukemia and the certain immunosuppressive therapies esp. B-cell targeting therapies. Thus the wide range of IgG usage in multiple treatments for on-label and off-label prescription will continue to expand and drive IgG demand across the global market in the coming years.

Middle East & Africa Blood Plasma Derivatives Market Overview

The Middle East & Africa blood plasma derivatives market has been segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share and is expected to boost moderately in the Middle East & Africa. The region has a significant prevalence of hemophilia, von Willebrand disease, and other bleeding disorders, increasing the adoption of plasma derivatives products for treatment. Furthermore, various partnerships between the market players and the government are also boosting the adoption of plasma derivatives for treatment boosting the market growth. For instance, in October 2021, Grifols and National Service Projects Organization (NSPO) Egypt inaugurated the first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines. This will enhance access to plasma products in the Middle East, Africa, and other countries boosting the market growth.

Middle East & Africa Blood plasma derivatives Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Blood Plasma Derivatives Strategic Insights

Strategic insights for the Middle East & Africa Blood Plasma Derivatives provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Blood Plasma Derivatives Report Scope

Middle East & Africa Blood Plasma Derivatives Regional Insights

The geographic scope of the Middle East & Africa Blood Plasma Derivatives refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Blood plasma derivatives Market Segmentation

The Middle East & Africa blood plasma derivatives market is segmented into type, application, end user, and country.

The Middle East & Africa blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held a larger market share in 2022.

Based on application, the Middle East & Africa blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held the largest share of the market in 2022.

The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held the largest share of the market in 2022.

Based on country, the Middle East & Africa blood plasma derivatives market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; CSL Behring LLC; LFB SA; Kedrion SpA; and Fusion Health Care Pvt Ltd are the leading companies operating in the Middle East & Africa blood plasma derivatives market.